Antibiotic resistance is a growing concern in the treatment of infectious disease worldwide. Point-of-care (PoC) assays which rapidly identify antibiotic resistance in a sample will allow for immediate targeted therapy which improves patient outcomes and helps maintain the effectiveness of current antibiotic stockpiles. Electrochemical assays offer many benefits, but translation from a benchtop measurement system to low-cost portable electrodes can be challenging. Using electrochemical and physical techniques, this study examines how different electrode surfaces and bio-recognition elements, i.e. the self-assembled monolayer (SAM), affect the performance of a biosensor measuring the hybridisation of a probe for antibiotic resistance to a target gene sequence in solution. We evaluate several commercially available electrodes which could be suitable for PoC testing with different SAM layers and show that electrode selection also plays an important role in overall biosensor performance.

Vincent J Vezzaa, Adrian Butterwortha, Perrine Lasserrea, Ewen O Blaira, Alexander MacDonalda, Stuart Hannaha, Christopher Rinaldib, Paul A Hoskissonc, Andrew C Wardd, Alistair Longmuire, Steven Setforde, Eoghan CW Farmerf, Michael...

No abstract

SARS-CoV-2 diagnostic practices broadly involve either quantitative polymerase chain reaction (qPCR)-based nucleic amplification of viral sequences or antigen-based tests such as lateral flow assays (LFAs). Reverse transcriptase-qPCR can detect viral RNA and is the gold standard for sensitivity. However, the technique is time-consuming and requires expensive laboratory infrastructure and trained staff. LFAs are lower in cost and near real time, and because they are antigen-based, they have the potential to provide a more accurate indication of a disease state. However, LFAs are reported to have low real-world sensitivity and in most cases are only qualitative. Here, an antigen-based electrochemical aptamer sensor is presented, which has the potential to address some of these shortfalls. An aptamer, raised to the SARS-CoV-2 spike protein, was immobilized on a low-cost gold-coated polyester substrate adapted from the blood glucose testing industry. Clinically relevant detection levels for SARS-CoV-2 are achieved in a simple, label-free measurement format using sample incubation times as short as 15 min on nasopharyngeal swab samples. This assay can readily be optimized for mass manufacture and is compatible with a low-cost meter.